Eli Lilly (LLY) announced on Wednesday that a late-stage trial designed to test a combination regimen containing its weight loss therapy Zepbound and psoriasis therapy Taltz reached the main goals.
Citing topline data, the Indiana-based drugmaker said that its TOGETHER-PsO open-label Phase 3b trial met the primary endpoint and a key secondary endpoint in obese or overweight patients with plaque psoriasis, the most common form of psoriasis.
As for the primary endpoint, over 36 weeks, 27% of patients on the drug combo achieved at least 10% weight loss and witnessed complete skin clearance as measured by the Psoriasis Area Severity Index ((PASI) 100)). In comparison, 5.8% of those on Taltz alone achieved at least 10% weight loss and PASI 100.
In a key secondary endpoint, patients on the combination regimen were 40% more likely to achieve PASI 100 compared to those who received Taltz as a single agent.
The 52-week open-label trial enrolled 274 adults with moderate-to-severe plaque psoriasis and obesity or overweight, as well as at least one weight-related condition.
As for safety, LLY reported generally mild to moderate adverse events following the administration of Taltz and Zepbound together. The kind of adverse events the patients experienced was roughly in line with the known tolerability profile of each drug, Lilly (LLY) added.
The company intends to discuss the results with global health regulators and submit 36-week data from the trial for publication in a peer-reviewed journal.